Close to 90% of people with moderate-to-severe hidradenitis suppurativa (HS) treated with bimekizumab (Bimzelx, UCB) remained free of flares for three years, according to a new post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, CO.The three-year data from the BE HEARD extension trial (BE HEARD EXT) included 347 HS patients who completed Week 148. Of those who entered BE HEARD EXT, the cumulative proportion who were free of acute exacerbation of symptoms (defined as a ≥25% increase in abscess and inflammatory nodule (AN) count versus baseline with an absolute increase in AN count of ≥2) at any scheduled clinic visit up to three years was 86.1%, the study showed.
Shorter disease duration and lower HS severity were associated with improved outcomes at three years, the researchers report. Bimekizumab’s efficacy improved over three years across all HS population subgroups, including BMI, age, disease duration, sex, and disease severity.
Baseline HS Characteristics May Influence Long-term Outcimes
In a separate post hoc analysis, Hidradenitis Suppurativa Clinical Response (HiSCR) response at three years was assessed for patients in the lowest disease duration quartile (<2.38 years since HS diagnosis) with moderate baseline disease severity (as defined by Hurley Stage II) vs. highest disease duration quartile (≥10.74 years since HS diagnosis) with severe baseline disease severity (as defined by Hurley Stage III).
At three years, HiSCR90/100 was achieved by 74.1% (43/58)/62.1% (36/58), respectively, in those with the lowest disease duration and moderate baseline HS, vs. 51.5% (17/33)/33.3% (11/33), respectively, with the highest disease duration and severe baseline HS, the study showed.
“One of the most important findings in the subgroup analysis is that responses seemed to generally be maintained or even improve as more time passed,” says Christopher J. Sayed, MD, a Dermatologist at the University of North Carolina Chapel Hill’s HS Clinic in Durham, NC, in an interview with The Dermatology Digest. He was a study author for the subgroup analysis. “For many patients achieving lower improvement thresholds after the first year, higher thresholds like HiSCR90 or HiSCR100 were met by year three, indicating that durable disease control leads to continued healing.”
Moreover, trends showed that those with prior biologic use and more advanced Hurley III disease responded at slightly lower levels at Year 1 and 2, but caught up by Year 3. This “indicates that even severe and recalcitrant disease can improve substantially with adequate time on treatment.”